The pre-apheresis peripheral blood CD34 þ cell count (PBCD34) is the strongest predictor of the number of stem cells collected. It is common practice to apherese only when PBCD34 is X5/ll to avoid poor yields. However, in patients with compromised marrow function, the only way to get enough cells is to collect small numbers daily several times. Another pitfall with this practice is not accounting for weight. We studied 285 autologous collections performed with PBCD34 o5/ll. The blood volume processed was 15 l (n ¼ 68) or 20 l (n ¼ 217). A collection of X0.3 Â 10 6 CD34 þ cells per kg ideal body weight (IBW) was considered acceptable as this daily yield over a week could total X2 Â 10 6 /kg-enough for an autograft. Two hundred and four harvests (72%) had yields of X0.3; with 59% being X0.4, 47% being X0.5 and 36% being X0.6. There were 23 patients whose harvests done when PBCD34 was low totaled X2 Â 10 6 /kg. Assuming a 20-l apheresis with 70% collection efficiency, we suggest harvesting if 14 n/w X0.3, where n ¼ PBCD34 and w ¼ IBW. This approach is more logical than using an absolute threshold, and will ensure that patients are not deprived of the opportunity of stem cell collection and autotransplantation.
Introduction
Blood has replaced bone marrow as the source of hematopoietic stem cells for autologous transplantation because of faster engraftment and immune reconstitution, and convenience. The quantity of CD34 þ cells infused impacts the speed of hematologic recovery.
1,2 The preleukapheresis peripheral blood CD34 þ cell count (PBCD34) is the strongest predictor of the CD34 þ cell yield. [3] [4] [5] The other factors that influence CD34 þ cell yield are the volume of blood processed and the collection efficiency (CE) of the procedure. 4, 5 Many centers use 5 cells per microliter (or even higher) as a minimum PBCD34 threshold to start harvesting stem cells. [6] [7] [8] Although the logic behind this practice is to avoid the inefficiency and cost of collections with poor yields, it results in the exclusion of a number of patients from harvest-and eventually from potentially life-saving autotransplantation. This threshold is somewhat arbitrary because it does not take into account the blood volume processed, the patient's weight and the CE-three of the four variables that affect the number of CD34 þ cells collected with a given apheresis procedure (the fourth being PBCD34). This problem is illustrated in Figure 1 .
Collecting small numbers of stem cells over several harvests may afford these patients an opportunity to undergo transplantation. Our practice has been to attempt a harvest as long as there are detectable circulating CD34 þ cells on flow cytometry. The aim of this retrospective study is to investigate the outcome of apheresis procedures done with PBCD34 o5/ml and develop a rational approach to harvesting on the basis of the patient's ideal body weight (IBW).
Patients and methods
Sixteen hundred and twenty-nine consecutive leukapheresis procedures performed over 5 years, which fulfilled the inclusion criteria, were studied: autologous harvests, patients with hematological malignancies, pre-apheresis PBCD34 available. Among these, 285 procedures were done in 129 patients (1-9 procedure per patient; median 2) when the PBCD34 was o5/ml. Blood volume processed was X15 l. Thus, not all apheresis procedures done during the specified time period were studied. Excluded from analysis were procedures for which PBCD34 was not available, allogeneic collections, and all aphereses for diseases other than hematologic malignancies. The overwhelming majority of patients had multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's disease or AML.
All experimental or research protocols were approved by the Institutional Review Board, as was this retrospective analysis. All patients provided informed consent for the procedure.
Apheresis technique
Cobe Spectra cell separators (Gambro BCT, Lakewood, CO, USA) running the semi-automated mononuclear cell collection protocol (version 6.1) according to the manufacturer's recommendations were used for leukapheresis. A large volume of leukapheresis was performed at a blood flow rate of 70-100 ml/min. The blood volume processed was 15-20 l.
Cell counts and yields CD34 þ cells were enumerated using standard techniques on the peripheral blood prior to leukapheresis and on the apheresis product prior to processing and cryopreservation.
The CD34 þ CE was the proportion (expressed as %) of the total CD34 þ cells processed (that is, passing through the cell separator) that were harvested. It was calculated using the following formula:
Total number of CD34 þ cells collected ðPBCD34Âblood volume processedÂ10 4 
Þ
In the above formula, the numerator represents the actual number of cells collected, PBCD34 is expressed in the number of cells per microliter and the blood volume processed is expressed in liters. The denominator should have 10 6 to convert liter to microliter and the numerator should have 100 to convert proportion to percent-this is more simply expressed as 10 4 in the denominator. For example, if 50 Â 10 6 CD34 þ cells were collected during a 20-l ( ¼ 20 Â 10 6 ml) procedure with PBCD34 of 10/ml, this would imply that 10 Â 20 Â 10 6 CD34 þ cells passed through the machine and 50 Â 10 6 (25%) were collected. The above formula thus becomes:
Statistical analysis and assumptions Cell yields were calculated by IBW based upon our experience. 2 A cumulative yield of X2 Â 10 6 CD34 þ cells per kg IBW was considered adequate for transplantation based on the published literature. A single collection of 0.3 Â 10 6 CD34 þ cells per kg was considered acceptable on the assumption that such a daily yield over a full week would add up to the threshold needed for transplantation.
For the purposes of analysis, each individual apheresis procedure was considered as a separate event. The data were analyzed for correlation using Excel 2003 for Windows.
Estimation of clinical benefit
For each individual patient, the total number of CD34 þ cells collected from this series of 285 collections (that is, only when PBCD34 was o5/ml) was calculated to see if it reached the threshold of 2 Â 10 6 /kg. It should be noted that this number would be expected to underestimate the number of patients benefiting from this approach because it does not account for patients whose total stem cell harvest reached the threshold of 2 Â 10 6 /kg due to a mixtures of collections done when PBCD34 was o5/ml (studied here) and X5/ml (not studied here).
Results
The 285 harvests studied resulted in the collection of 0-2.03 Â 10 6 CD34 þ cells per kg (median 0.47). The correlation between cell yield and PBCD34 in this group was modest (r ¼ 0.40) in contrast to the harvests done when PBCD34 was X5/ml (r ¼ 0.93). The CD34 þ cell CE during these 285 harvests was 0-299% (median 53%; X70% in 27%). In comparison, CE for the other 1344 harvests was 3-146% (median 44%; Po0.0001). Of these 285 harvests, 204 harvests (72%) had CD34 þ cell yields of X0.3; with 59% being X0.4, 47% being X0.5 and 36% being X0.6. Twenty-three patients were found to have collected a total of X2 Â 10 6 CD34 þ cells per kg exclusively over the low PBCD34 collections (that is, excluding collections they may have had when PBCD34 was X5). Details of these patients have been shown in Table 1 . Among 19 patients, the collection occurred over a single mobilization/harvest attempt, 3 (patients 2-22) required 2 attempts and 1 (patient 23) required 3 attempts. The numbers in parentheses in the second column show the number of collections per attempt in these 4 patients.
Based on the fact that almost three-quarters of the harvests resulted in the collection of X0.3 Â 10 6 CD34 þ cells per kg and that this daily yield could result in the goal of 2 Â 10 6 CD34 þ cells per kg being reached in a week, we felt that this was a reasonable minimum projected collection per apheresis to decide whether a patient should be apheresed or not.
The formula to determine this, assuming a 20-l blood volume processed and a 70% CD34 þ cell CE, is 14 n/w. In this, n is PBDC34 (number of cells per microliter) and w is the IBW in kilograms. This formula has been derived from the CE formula by putting in assumed CE (70) and blood volume (20) values, and factoring in patient weight. Thus:
4 Þ=wX0:3Â10 6 which reduces to 14n=wX0:3 If 14 n/w is X0.3, a minimum of 0.3 Â 10 6 CD34 þ cells per kg would be expected to be collected-and the patient should be put on the machine. On the other hand, if 14 n/w is o0.3, the yield would be too poor to complete apheresis in a week-and the patient need not be harvested. Applying this formula retrospectively to the current series, 16 apheresis procedures would have been avoided-with projected collections of o0.3 Â 10 6 CD34 þ cells per kg. In practice, 12 of these 16 procedures had cell yield of less than 0.3 and four had X0.3.
Lastly, 18 patients actually underwent autotransplantation using only these cells or with a quantity of cells that included mostly these cells: the time to 0.5 Â 10 9 /l neutrophils was 11-16 days (median 12), the time to 1.0 Â 10 9 /l neutrophils was 11-18 days (median 12), platelet recovery to 20 Â 10 9 /l occurred within 21 days in 12 patients and platelet recovery to 50 Â 10 9 /l occurred within 21 days in 6 patients. No graft failure or transplant-related mortality occurred.
Discussion
Most work done so far has concentrated on identifying PBCD34 thresholds that would make the apheresis process more successful in terms of the proportion of harvests that would result in good cell yields in a single run (variably defined; for example, 'enough for a single transplant,' 'at least 2 Â 10 6 CD34 þ cells per kg', and so on.). Based on these, the thresholds that have been proposed are 5, 10 or even 20 circulating CD34 þ cells per microliter. [6] [7] [8] Although enforcement of such CD34 þ cell count levels Table 1 Twenty-three patients in whom a target of X2 Â 10 6 CD34+ cells per kg was reached solely from collections done when PBCD34 was o5/ml decreases the number of apheresis procedures required and increases technically defined success rates, it also excludes poor mobilizers from apheresis-and deprives them of the ability to undergo transplantation. With patients' therapy rather than the number of apheresis procedures in mind, our approach has been to be as inclusive as possible in selecting patients for apheresis. An aim of this project was to evaluate the practice of subjecting patients to apheresis as long as there were circulating CD34 þ cells. The data shown here, in our opinion, justify the practice in most cases. At least 23 patients reached the goal of 2 Â 10 6 CD34 þ cells per kg on the basis of collections done when PBCD34 was low. This represents an underestimate of the benefit because it excludes patients whose total cell yield from aphereses done when PBCD34 was X5/ml, was still short of the desired target-and collections done when PBCD34 was o5/ml helped them reach the target.
If performing apheresis whenever there are any circulating CD34 þ cells is an approach that is felt to be excessively liberal, we propose using a formula to facilitate the decision that takes into account all the variables-and is not an arbitrary number. The formula we have proposed is 14 n/w X0.3. Based upon local practices, the formula could be changed for each institution. For example, if 30 l blood is to be processed with a 70% CE (27% of procedures in this study), the formula will be 21 n/w X0.3-and will exclude an even lower number of patients from apheresis (only five in this series; four of whom had poor collections). If 20 l blood is to be processed but the achievable CE is felt to be only 50%, the formula would be 10 n/w X0.3. The latter would have excluded 32 procedures, 21 of which had poor collections. Of course, this formula has been developed on retrospective data and needs to be validated on an independent sample and possibly also in a prospective study.
There are reports in the literature of successful bone marrow harvests when mobilization of stem cells into the bloodstream has failed. 9, 10 However, in both these studies, failure of mobilization was defined as PBCD34 o10/ml. Such patients did not undergo apheresis at all. This threshold can be considered questionable because a reasonably good CD34 þ cell collection from the blood is still possible under such circumstances-and it is probable that if a blood stem cell harvest had been attempted in these patients, the number of progenitor cells would have at least equaled if not exceeded what was obtained subsequently from the marrow. This is in keeping with the findings of Goterris et al.
11 who found that after failure of initial collection (CD34 þ cell yield o2 Â 10 6 /kg), a second-line blood harvest after repeat mobilization was more successful than a marrow harvest.
Indeed, we have done diagnostic bone marrow aspirations to check for CD34 þ cells by flow cytometry in a few patients who have been mobilized but have no detectable CD34 þ cell clusters on flow cytometry despite leukocyte counts in the 25-57 Â 10 9 /l range, to explore the feasibility of a marrow harvest-and have, without exception, found no detectable CD34 þ cells in the marrow either (unpublished data).
We conclude that attempting stem cell collection with low circulating CD34 þ cell numbers is justifiable in a substantial proportion of patients and that the practice of using a fixed numeric threshold for circulating CD34 þ cells to start apheresis should be abandoned in favor of a formula-based approach.
